New bisphosphonates in the treatment of bone metastases
โ Scribed by Steven D. Averbuch
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- English
- Weight
- 961 KB
- Volume
- 72
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## BACKGROUND. This study was conducted to review the efficacy and safety of oral bisphosphonates for the treatment of bone metastases in cancer patients. ## METHODS. Available published clinical studies of oral bisphosphonates in bone metastases from 1980 to the present were identified through a
ther studies have revealed that this drug has extremely potent effects on turnover of bone, and that low doses can be used to reduce bone resorption. Like the Developmental Chemotherapy Service, Departbisphosphonates, gallium nitrate has been studied in both malignant and in non-ment of Medicine, Me
Background and Objectives: Pathologic fractures due to disseminated metastases are common and often involve major long bones, where the metastasis is responsible for wide bone erosion that is equivalent to major bone loss. Stabilization of these fractures necessitates tumor excision and reconstructi
YH529, [1-hydroxy-2-(imidazo [1,2-a] pyridin-3-yl) ethylidene]-bisphosphonic acid monohydrate, is a newly developed third-generation bisphosphonate with a potent inhibitory activity toward osteoclastic bone resorption. The primary cellular mechanism of osteolysis associated with metastatic cancer is